Research · Sep 3, 2026
[OGN] Organon Thesis 2026: Women Health Biosimilars Established Brands Post Merck Spin Off Compounder
Organon & Co (NYSE: OGN), headquartered in Jersey-City-NJ, is a Women-Health-and-Biosimilars-and-Established-Brands-Post-Merck-Spin-Off + emerging-multi-cycle-Vtama-and-Women-Health-Cycle leader providing distinctive multi-cycle Established-Brands-NuvaRing-and-Mercilon-and-Marvelon-and-Singulair-and-Zocor-and-Cozaar + emerging-Women-Health-Nexplanon-and-Saxenda + emerging-Vtama-Plaque-Psoriasis-Acquired-2024-Dermavant + emerging-Biosimilars-Renflexis-and-Brenzys-and-Hadlima-and-Aybintio services to substantial multi-cycle US-and-International-Women-Health-Patient + Established-Brands-Patient-Population + Vtama-Plaque-Psoriasis-Patient (~7.5M-8.0M US) + Biosimilars-Customer-International-and-US customer base. The company has distinctive multi-cycle Organon-and-Jersey-City-NJ-and-Women-Health-Biosimilars-Established-Brands heritage: founded 2021 as Organon-via-Merck-Spin-Off + 2021-NYSE-Organon-Spin-Off-from-Merck-IPO ($9.0B+ Spin-Off-Value); 2021-2024-Multi-Cycle-Established-Brands-Cycle + emerging-Vtama-Plaque-Psoriasis-and-Women-Health-and-Biosimilars-Cycle; 2024-Dermavant-Vtama-Plaque-Psoriasis-acquired ($1.2B+ providing emerging-multi-cycle-Vtama-Plaque-Psoriasis-Roivant-Sciences-Subsidiary); 2024-Dividend-Cut-and-Conservative-Debt-Paydown + Multi-Cycle-Conservative-Capital-Management; multi-cycle-disciplined-Women-Health-Biosimilars-Established-Brands-Capital-Management; Kevin-Ali-CEO-since-2021-Spin-Off-CEO + Multi-Cycle-Organon-Capital-Management leadership-continuity. FY2025 closes with selected various aggregate revenue ~$6.05-6.55B (~-2 to +4% YoY-reflecting Established-Brands-Cycle + emerging-Vtama-Plaque-Psoriasis-and-Women-Health-and-Biosimilars-Cycle + emerging-Dermavant-Vtama-Acquired-2024-Revenue-Contribution), adjusted EBITDA ~$1,760-1,985M (~28-32% margins), adjusted EPS ~$3.85-4.85, net debt ~$8.40-9.05B (~4.5-5.0x leverage), and ~257-260M shares outstanding. The Established-Brands-and-Women-Health-and-Vtama-Plaque-Psoriasis-and-Biosimilars franchise deep-dive covers distinctive multi-cycle ~10,000-10,500 employees + ~Jersey-City-NJ-HQ + ~Globally-Positioned-Pharmaceutical-and-Biosimilars-Manufacturing-Facility, Established-Brands ~50-55% revenue + Women-Health ~22-28% revenue + Biosimilars-and-Vtama-Plaque-Psoriasis ~18-25% revenue, substantial multi-cycle US-and-International-Women-Health-Patient + Established-Brands-Patient-Population + Vtama-Plaque-Psoriasis-Patient (~7.5M-8.0M US) + Biosimilars-Customer-International-and-US + NuvaRing-and-Nexplanon-Long-Acting-Reversible-Contraception-Patient + Plaque-Psoriasis-Topical-Steroid-Sparing-Patient customer base, 2021-Organon-Spin-Off-from-Merck + 2021-NYSE-Organon-Spin-Off-IPO ($9.0B+) + 2024-Dermavant-Vtama-acquired ($1.2B+) + 2024-Dividend-Cut-and-Conservative-Debt-Paydown transformational-platform, emerging-multi-cycle Established-Brands-Cycle + emerging-Vtama-Plaque-Psoriasis-Acquired-2024 + emerging-Women-Health-Nexplanon-Cycle + emerging-Biosimilars-Cycle + emerging-Conservative-Debt-Paydown-Post-2024-Dividend-Cut + emerging-Multi-Cycle-Established-Brands-and-Specialty-Pharma-Mix-Shift structural-tailwinds, competing in Women-Health-and-Biosimilars-and-Established-Brands space with Merck, Bayer, Pfizer, Johnson & Johnson, AbbVie, Eli Lilly, Bristol-Myers Squibb, Novartis, Sandoz (Novartis-Biosimilars-Spin-Off-2023), Roche, GSK, Sanofi, Teva Pharmaceutical, Viatris, Amneal Pharmaceuticals, Coherus BioSciences, Dermavant-Vtama-acquired-Organon-2024, Roivant Sciences (Dermavant-divestor-2024); and private-equity-Apollo-KKR-Blackstone-Carlyle-Bain-CD&R-EQT-Permira-CVC-Bridgepoint-Cinven-Ardian-TPG-Veritas-Genstar. The Kevin-Ali + 2021-Spin-Off-CEO + 2021-Merck-Spin-Off-and-2024-Dermavant-Vtama-Acquired deep-dive covers Kevin-Ali-CEO (since-Founder-2021-Spin-Off-CEO + Former-Merck-Senior-Executive-Worldwide-Markets-and-Established-Brands) + multi-cycle-Organon-Capital-Management leadership-continuity expertise, multi-cycle-disciplined-Women-Health-Biosimilars-Established-Brands-Capital-Management discipline, multi-cycle-emerging-Reduced-Dividend (~$0.16/yr Post-2024-Dividend-Cut, ~3.5-5.0% yield, ~4-7% EPS payout-Post-Cut, ~3+ year continuous post-2024-Dividend-Cut) + multi-cycle-emerging-share-buyback-suspended. Capital position is Sub-IG (Ba2/BB to Ba1/BB+ ~4.5-5.0x leverage). At ~$10-18 per share, equity value ~$2.55-4.65B, EV ~$11.0-13.5B, providing ~2-5x EPS and ~6-7x EV/EBITDA.